Vivus Escapes Shareholder Suit Over Obesity Drug Safety

Law360, New York (September 28, 2012, 3:43 PM EDT) -- A California federal judge on Thursday dismissed a putative class action accusing drugmaker Vivus Inc. of lying to investors about the risks of its recently approved obesity treatment Qsymia, ruling the company had made adequate disclosures about the drug.

U.S. District Judge Phyllis J. Hamilton said that Mountain View, Calif.-based Vivus had not hidden the risks of Qsymia in an attempt to mislead investors about the chances of U.S. Food and Drug Administration approval for the drug, having consistently made available information about the nature and...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Kovtun v. Vivus, Inc. et al


Case Number

4:10-cv-04957

Court

California Northern

Nature of Suit

Securities/Commodities

Judge

Phyllis J. Hamilton

Date Filed

November 2, 2010

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.